OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

News


perlinnew

David S. Perlin, Ph.D.

Posted .

Dr. David Perlin is Executive Director of the UMDNJ/New Jersey Medical School’s Public Health Research Institute (PHRI), a 72 year old specialized center for global infectious diseases research. He is also Director of the new UMDNJ Regional Biocontainment Laboratory, one of thirteen national centers, and a Professor of Microbiology and Molecular Genetics. Dr. Perlin helped establish PHRI as a leading tuberculosis and opportunistic infections research organization. His primary expertise is in fungal infections, antifungal drug resistance and rapid diagnosis of opportunistic drug resistant pathogens in high-risk patients. His laboratory is supported by grants from the NIH, pharma and biotech sectors. He is on the editorial board of several scientific journals and serves on the Board of Directors of the Aaron Diamond AIDS Research Center and Scientific/Medical Advisory Boards for pharma and biotech companies, and PinnacleCare. He is also a member of the New York City Department of Health and Mental Hygiene Advisory Panel on Bioterrorism and Emerging Infections and the Executive Committee of the Northeast Biodefense Center.

 

Dr. Perlin earned an AB degree from Brandeis University in 1976 and a Ph.D. from Cornell University in 1980. He pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin joined PHRI in 1985; he was named Scientific Director in 1992, President in 2005, and Director of the new UMDNJ Center in 2006. He was appointed Professor of Microbiology and Molecular Genetics in 2003 and Executive Director of PHRI and the national Regional Biocontainment Laboratory in 2010. Dr. Perlin was named a Fellow of the New York Academy of Sciences in 2005 and a Visiting Professor at the University of Manchester, UK in 2009.